Ferrer
Ferrer, officially known as Ferrer Internacional, is a prominent global pharmaceutical and healthcare company headquartered in Spain. Established in 1959, Ferrer has made significant strides in the industry, focusing on the development of innovative solutions in pharmaceuticals, biotechnology, and consumer health. With a strong presence in Europe, Latin America, and Asia, the company is dedicated to improving patient outcomes through its diverse portfolio. Ferrer’s core offerings include prescription medicines, over-the-counter products, and advanced biopharmaceuticals, distinguished by their commitment to quality and innovation. The company has achieved notable recognition for its research-driven approach and has established itself as a key player in the healthcare sector. With a focus on sustainability and social responsibility, Ferrer continues to enhance its market position while striving to meet the evolving needs of patients worldwide.
DitchCarbon Score
How does Ferrer's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ferrer's score of 45 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ferrer's reported carbon emissions
In 2023, Grupo Ferrer Internacional reported total carbon emissions of approximately 72,902,000 kg CO2e, with Scope 1 emissions at about 7,322,000 kg CO2e and Scope 3 emissions at approximately 65,580,000 kg CO2e. This marked a decrease from 2022, where total emissions were about 81,436,000 kg CO2e. Ferrer has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 46.2% by 2030, using 2019 as the base year. Additionally, the company plans to increase its annual sourcing of renewable electricity from 95% in 2019 to 100% by 2030. For Scope 3 emissions, Ferrer targets a reduction of 27.5% by 2030 from the same base year. Furthermore, the company commits to ensuring that 91% of its suppliers, based on spend covering purchased goods and services, will have science-based targets by 2024. These initiatives align with industry standards for climate action, demonstrating Ferrer's commitment to sustainability and reducing its carbon footprint in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 8,369,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,970,000 | 0,000,000 | 000,000 | 000,000 | - | - | - |
| Scope 3 | 21,498,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ferrer is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
